European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide, vilanterol - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - laventair ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - venlabic xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - venlafaxine hydrochloride, quantity: 84.9 mg (equivalent: venlafaxine, qty 75 mg) - capsule, modified release - excipient ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlabic xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlabic xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Ireland - English - HPRA (Health Products Regulatory Authority)

db ashbourne ltd - venlafaxine hydrochloride - tablet prolonged release - 75 milligram - other antidepressants

Ireland - English - HPRA (Health Products Regulatory Authority)

db ashbourne ltd - venlafaxine hydrochloride - tablet prolonged release - 150 milligram - other antidepressants

Ireland - English - HPRA (Health Products Regulatory Authority)

db ashbourne ltd - venlafaxine hydrochloride - tablet prolonged release - 225 milligram - other antidepressants

Ireland - English - HPRA (Health Products Regulatory Authority)

db ashbourne ltd - venlafaxine hydrochloride - tablet prolonged release - 37.5 milligram - other antidepressants

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - venlafaxine hydrochloride - modified-release tablet - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ethypharm uk ltd - venlafaxine hydrochloride - modified-release tablet - 75mg